Seroquel XR in Schizophrenia Relapse Prevention

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00990626

Enrollment

1600

Registered

2009-10-07

Start date

2009-10-31

Completion date

2010-07-31

Last updated

2010-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia Relapse Prevention

Keywords

Seroquel XR, schizophrenia relapse prevention

Brief summary

The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improve the relapse prevention in schizophrenic outpatients

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Schizophrenic outpatients on at least 600 mg Seroquel XR treatment for at least 1 month

Exclusion criteria

* Severe cerebro- and cardiovascular disease, severe hepatic impairment, gravidity

Design outcomes

Primary

Measure	Time frame
Rate of patients remained relapse free after 6 months of treatment	—

Secondary

Measure	Time frame
Adherence rate of patients	—
Quality of Life (QoL )	—

Countries

Hungary

Outcome results